Newly reported from EULAR 2024: SEL-212 Demonstrates Clinical Safety, Efficacy in Gout

Newly reported from EULAR 2024: SEL-212 Demonstrates Clinical Safety, Efficacy in Gout Both SEL-110 high dose (HD, 0.15 mg/kg) or low dose (LD, 0.1 mg/kg) with concomitant SEL-037 (0.2 mg/kg), known as SEL-212, demonstrated clinical efficacy and safety among a cohort of patients with gout refractory to standard treatment, according to data presented at the 2024 European Congress of Rheumatology (EULAR). As […]

From EULAR 2024 – Gerd Burmester, MD: Long-Term Data Supports Upadacitinib’s Safety in Rheumatic Disease Treatment

From EULAR 2024 – Gerd Burmester, MD: Long-Term Data Supports Upadacitinib’s Safety in Rheumatic Disease Treatment In an interview with HCPLive, Gerd Burmester, MD, professor of medicine in the Department of Rheumatology and Clinical Immunology at the Charité University Hospital, Free University of Berlin, and Humboldt University of Berlin, Germany, discusses the results of a study […]

Reporting from EULAR 2024: Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA

Reporting from EULAR 2024: Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA Despite the numerous treatments available, psoriatic arthritis (PsA) remains multifaceted and heterogeneous. Patient presentations and needs can vary significantly, necessitating tailored treatments. The current challenge is to find a drug that balances efficacy and safety to address these diverse patient […]

Broadcasting from EULAR 2024: Canakinumab Prophylaxis Resolves Active Gout Flares Within 48 Hours

Broadcasting from EULAR 2024: Canakinumab Prophylaxis Resolves Active Gout Flares Within 48 Hours Canakinumab prophylaxis resolves active gout flares within 48 hours and prevents new gout flares among patients initiating pegloticase + methotrexate, according to a study presented at the 2024 European Alliance of Associations for Rheumatology (EULAR) in Vienna, Austria. The US Food and Drug Administration […]

Newly reported from EULAR 2024: High Fatigue Rates Exist in Economically Disadvantaged Patients with RA

Newly reported from EULAR 2024: High Fatigue Rates Exist in Economically Disadvantaged Patients with RA A recent study highlighted the substantial prevalence of severe fatigue among poor patients with rheumatoid arthritis (RA). Investigators presented the data at the 2024 European Alliance of Associations for Rheumatology (EULAR) from June 12 – 15, in Vienna, Austria. “Younger age, smoking, […]

Reporting from EULAR 2024: Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA

Reporting from EULAR 2024: Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA Among patients with rheumatoid arthritis (RA), treatment with the adalimumab biosimilar MSB11022 was shown to sustain the prior benefits reported in previous adalimumab treatment, according to data presented at the 2024 European Congress of Rheumatology (EULAR). In some cases, treatment with the biosimilar led to greater improvements […]

Broadcasting from EULAR 2024: Dazodalibep Significantly Improves Disease Activity in Rheumatoid Arthritis

Broadcasting from EULAR 2024: Dazodalibep Significantly Improves Disease Activity in Rheumatoid Arthritis Dazodalibep significantly improves disease activity and swollen and tender joint counts in patients with moderate-to-severe active rheumatoid arthritis (RA), according to new findings from the Phase 2 MIDORA clinical trial. The drug, a non-antibody fusion protein that targets CD40L, also reduced biomarkers of T- […]

Directly from EULAR 2024: Study Reveals Romosozumab, Denosumab Effectively Treats RA Complicated with Osteoporosis

Directly from EULAR 2024: Study Reveals Romosozumab, Denosumab Effectively Treats RA Complicated with Osteoporosis Treatment with romosozumab or denosumab among patients with either primary osteoporosis or rheumatoid arthritis (RA) complicated with osteoporosis (RA-OP) demonstrated clinical efficacy over separate 12-month treatment periods, according to a prospective cohort study presented at the 2024 European Congress of Rheumatology (EULAR). Investigators believe these […]